The Top 5 Analyst Questions From Guardant Health's Q1 Earnings Call

Guardant Health’s first quarter results were driven by strong growth in its core oncology business and continued momentum for its new Shield screening product. Management attributed the quarter’s performance to volume acceleration in Guardant360 and Reveal, supported by upgrades to its smart liquid biopsy platform and expanded reimbursement coverage. Co-CEO Helmy Eltoukhy emphasized the impact of workflow improvements, noting that Reveal achieved gross margin positivity for the first time, mainly due to a greater than 50% reduction in cost per test. The company also benefited from higher average selling prices (ASPs) for both Guardant360 and tissue-based tests, reflecting stronger reimbursement trends.

Is now the time to buy GH? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions Guardant Health’s Q1 Earnings Call

• Mark Massaro (BTIG) asked about the drivers behind accelerating oncology volume growth. Co-CEO Helmy Eltoukhy attributed it to product upgrades, particularly the smart liquid biopsy platform, and increased adoption of both Guardant360 and Reveal.
• Tycho Peterson (Jefferies) questioned Shield’s ASP guidance given the ADLT price increase. CFO Mike Bell clarified that the blended ASP reflects a mix of Medicare, Medicare Advantage, and commercial payers, with room for further improvement as collections stabilize.
• Bill Bonello (Craig-Hallum) inquired whether the new tissue test could cannibalize liquid biopsy volumes. Eltoukhy responded that both tissue and liquid modalities are increasingly used together, and the upgraded tissue test should expand the total addressable market rather than shift volume.
• Subbu Nambi (Guggenheim Partners) asked about factors that could drive upside or downside to Shield volume guidance. Co-CEO AmirAli Talasaz cited sales force productivity, guideline inclusion, and large contracts such as with the VA and Abu Dhabi as key variables.
• Rachel Vatnsdal (JPMorgan) pressed on the expected ramp of Shield volumes through the year. Talasaz reiterated that growth is expected to be weighted to the second half due to the time required for sales reps to reach full productivity.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will monitor (1) Shield’s volume trajectory as new sales reps come online and as reimbursement gains are realized, (2) the impact of additional clinical publications and potential inclusion in screening guidelines, and (3) further adoption of the upgraded Guardant360 Tissue test. Progress on these milestones, along with updates on biopharma partnerships, will be critical to tracking Guardant’s execution.

Guardant Health currently trades at $50.89, up from $47.17 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

The Best Stocks for High-Quality Investors

Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.

While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.